In a pre-clinical setting, numerous STING agonists such as DMXAA or ADU-S100 have shown promising results by inducing a potent anti-tumor immune response either alone or in combination with other conventional cancer therapies including radio- and chemotherapy (277–281). Here, STING1 is linked to cancer.